In today’s increasingly complex and competitive pharma market, what does it take to rise above?
This question is especially layered for contract manufacturers, who must take on all the efficiency, quality and cost challenges plaguing the broader pharma industry, while also competing within a crowded CDMO space.
There are currently over 500 pharma CDMOs in the world, all jockeying to carve out a unique niche for themselves in key sectors of the modern drug industry. New CDMOs braving this busy space must find a way to elevate themselves above the rest.
Clearly, it is no longer enough for CDMOs to simply offer excess manufacturing capacity. In addition to expertise in the toughest and most popular areas of pharma, such as cell and gene therapies or sterile injectables, companies must enter the sector with a certain bravado.
Oftentimes, this comes in the form of disruption — founders who survey the current landscape and believe there must be a better way. Other times it comes in the form of cutting-edge technology, and a willingness to go all-in. Companies must also serve as stewards of the environment, contribute to the community and offer an organizational culture that appeals to today’s workforce.
Put simply, modern therapies require modern CDMOs. The four young companies we’ve chosen to profile — ten23 health, Cellares, INCOG BioPharma Services and Matica Biotechnology — were launched, built and nurtured with intention. As a result, they have become key players among a new generation of CDMOs, well-positioned to boldly forge the future of pharma.
Read the 2024 profiles:
ten23 health: Embracing sustainability in sterile injectables
Cellares: A disruptive impact on cell therapy production
INCOG BioPharma Services: A transparent, flexible approach to injectables
Matica Biotechnology: Speeding CGTs to patients with advanced technologies
Read our past CDMO profile series:
2023: Built to thrive — Three CDMOs that set themselves up to flourish
2022: Bold ventures — Three CDMOs willing to chart new paths
